269 related articles for article (PubMed ID: 23469252)
21. Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
Du G; Liu T; Lewis MM; Kong L; Wang Y; Connor J; Mailman RB; Huang X
Mov Disord; 2016 Mar; 31(3):317-24. PubMed ID: 26362242
[TBL] [Abstract][Full Text] [Related]
22. Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.
Du G; Lewis MM; Shaffer ML; Chen H; Yang QX; Mailman RB; Huang X
PLoS One; 2012; 7(4):e35397. PubMed ID: 22530017
[TBL] [Abstract][Full Text] [Related]
23. Iron deposition in Parkinson's disease by quantitative susceptibility mapping.
Chen Q; Chen Y; Zhang Y; Wang F; Yu H; Zhang C; Jiang Z; Luo W
BMC Neurosci; 2019 May; 20(1):23. PubMed ID: 31117957
[TBL] [Abstract][Full Text] [Related]
24. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.
Martin WR; Wieler M; Gee M
Neurology; 2008 Apr; 70(16 Pt 2):1411-7. PubMed ID: 18172063
[TBL] [Abstract][Full Text] [Related]
25. Association of freezing of gait with nigral iron accumulation in patients with Parkinson's disease.
Naduthota RM; Honnedevasthana AA; Lenka A; Saini J; Geethanath S; Bharath RD; Christopher R; Yadav R; Gupta AK; Pal PK
J Neurol Sci; 2017 Nov; 382():61-65. PubMed ID: 29111022
[TBL] [Abstract][Full Text] [Related]
26. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects.
Bartzokis G; Cummings JL; Markham CH; Marmarelis PZ; Treciokas LJ; Tishler TA; Marder SR; Mintz J
Magn Reson Imaging; 1999 Feb; 17(2):213-22. PubMed ID: 10215476
[TBL] [Abstract][Full Text] [Related]
27. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease.
O'Neill J; Schuff N; Marks WJ; Feiwell R; Aminoff MJ; Weiner MW
Mov Disord; 2002 Sep; 17(5):917-27. PubMed ID: 12360540
[TBL] [Abstract][Full Text] [Related]
28. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
[TBL] [Abstract][Full Text] [Related]
29. Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease.
Bunzeck N; Singh-Curry V; Eckart C; Weiskopf N; Perry RJ; Bain PG; Düzel E; Husain M
Parkinsonism Relat Disord; 2013 Dec; 19(12):1136-42. PubMed ID: 24025315
[TBL] [Abstract][Full Text] [Related]
30. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.
Atasoy HT; Nuyan O; Tunc T; Yorubulut M; Unal AE; Inan LE
Neurol India; 2004 Sep; 52(3):332-7. PubMed ID: 15472421
[TBL] [Abstract][Full Text] [Related]
31. Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts.
Langley J; He N; Huddleston DE; Chen S; Yan F; Crosson B; Factor S; Hu X
Mov Disord; 2019 Mar; 34(3):416-419. PubMed ID: 30597635
[TBL] [Abstract][Full Text] [Related]
32. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
[TBL] [Abstract][Full Text] [Related]
33. Non-Motor Symptom Burdens Are Not Associated with Iron Accumulation in Early Parkinson's Disease: a Quantitative Susceptibility Mapping Study.
Shin C; Lee S; Lee JY; Rhim JH; Park SW
J Korean Med Sci; 2018 Mar; 33(13):e96. PubMed ID: 29573246
[TBL] [Abstract][Full Text] [Related]
34. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM
Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572
[TBL] [Abstract][Full Text] [Related]
35. Differential Effect of Iron and Myelin on Susceptibility MRI in the Substantia Nigra.
Lee H; Cho H; Lee MJ; Kim TH; Roh J; Lee JH
Radiology; 2021 Dec; 301(3):682-691. PubMed ID: 34609198
[TBL] [Abstract][Full Text] [Related]
36. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages.
Rossi ME; Ruottinen H; Saunamäki T; Elovaara I; Dastidar P
Acad Radiol; 2014 Jan; 21(1):64-71. PubMed ID: 24331266
[TBL] [Abstract][Full Text] [Related]
37. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
Wang C; Fan G; Xu K; Wang S
Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
[TBL] [Abstract][Full Text] [Related]
38. MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease.
Kosta P; Argyropoulou MI; Markoula S; Konitsiotis S
J Neurol; 2006 Jan; 253(1):26-32. PubMed ID: 15981079
[TBL] [Abstract][Full Text] [Related]
39. Effective R
Luo J; Collingwood JF
J Neurosci Methods; 2022 Dec; 382():109708. PubMed ID: 36089168
[TBL] [Abstract][Full Text] [Related]
40. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
